Shanghai Ark Biopharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Holding
- Established
- 2014-04-29
- Employees
- 51
- Market Cap
- -
Anti-RSV Study in Chinese Patients (ASCENT)
- First Posted Date
- 2018-10-09
- Last Posted Date
- 2019-11-27
- Lead Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 160
- Registration Number
- NCT03699202
- Locations
- 🇨🇳
Shenzhen People's Hospital, Shenzhen, China
🇨🇳China-Japan Friendship Hospital, Beijing, China
🇨🇳Beijing Pinggu Hospital, Beijing, China
A Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of AK0529
- First Posted Date
- 2018-01-17
- Last Posted Date
- 2018-09-11
- Lead Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 7
- Registration Number
- NCT03400995
- Locations
- 🇬🇧
Quotient Clinical, Nottingham, United Kingdom
A Study of AK0529 to Evaluate Pharmacokinetics and Safety in Chinese Healthy Volunteers
- First Posted Date
- 2017-10-26
- Last Posted Date
- 2021-06-09
- Lead Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 51
- Registration Number
- NCT03322800
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, China
Viral Inhibition in Children for Treatment of RSV
Phase 2
Completed
- Conditions
- RESPIRATORY SYNCYTIAL VIRUS INFECTIONS
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-01-13
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 72
- Registration Number
- NCT02654171
- Locations
- 🇦🇺
Gold Coast University Hospital, Gold Coast, Queensland, Australia
🇮🇱Soroka University Medical Center, Beer-Sheva, Israel
🇮🇱Schneider Children's Medical Center, Petach Tikvah, Israel
A Study of AK0529 in Infants Hospitalized With RSV
- First Posted Date
- 2015-06-02
- Last Posted Date
- 2018-07-02
- Lead Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 1
- Registration Number
- NCT02460016
- Locations
- 🇦🇺
Women's & Children's Hospital, Adelaide, South Australia, Australia
Safety, Tolerability and PK Study of AK0529 in Healthy Human
Phase 1
Completed
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-11-21
- Last Posted Date
- 2015-10-20
- Lead Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 74
- Registration Number
- NCT02297594
- Locations
- 🇦🇺
Q-Pharm Pty Ltd QIMR Berghofer & Royal Brisbane and Women's Hospital Campus, Brisbane, Queensland, Australia
© Copyright 2025. All Rights Reserved by MedPath